Companies /Healthcare

Biomarin Pharmaceutical Inc

NASDAQ: BMRN Biotechnology
$61.42
▼ $0.01 (−0.02%) today
Markets closed · 4:40pm ET

24/7 Wall St. View

BMRN at a Glance

Valuation
Market cap
$11.3B
Profitability
Revenue (TTM)
$3.7B
Profit margin
-0.5%
EPS (TTM)
$-0.10
Price
52-week range
$49 – $71
24/7 target
$89.46
Street target
$90.19
Earnings
Q3 2026 EPS
$0.23
vs. $-0.11 est.
+304.8%

Headquartered in San Rafael, CA Fiscal year ends December NASDAQ: BMRN biomarin.com

About BioMarin

BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company that develops and commercializes medicines for people with genetically defined conditions. It has nine commercial therapies plus a clinical and preclinical pipeline.

Its products fall into two main areas:
- **Skeletal conditions:** VOXZOGO for achondroplasia, its largest single product. More than 75% of VOXZOGO sales come from outside the U.S., and it is under review for hypochondroplasia.
- **Metabolic conditions:** VIMIZIM, NAGLAZYME, PALYNZIQ, BRINEURA and ALDURAZYME (the latter a BioMarin/Genzyme brand), plus GALAFOLD for Fabry disease and POMBILITI + OPFOLDA for late-onset Pompe disease. The last two came with the April 2026 acquisition of Amicus Therapeutics.

Other revenue comes from KUVAN, the gene therapy ROCTAVIAN (which it will no longer market) and royalties. Royalties now include payments from Ascendis on Yuviwel sales following a 2026 settlement.

BioMarin is building its pipeline through business development, with four deals in 2026:
- BMN 450, a subcutaneous enzyme replacement therapy for Fabry disease
- BMN 440, an oral therapy for hypophosphatasia (from the Alesta acquisition)
- BMN 430, an antisense oligonucleotide for ReNU syndrome
- BMN 820, an oral CCR2 inhibitor for FSGS, with U.S. rights

Internal programs include BMN 333, a long-acting CNP for achondroplasia, and BMN 351 for Duchenne muscular dystrophy. Revenue is generated worldwide, with significant exposure to large, timing-sensitive international government orders. Updated

Revenue by Segment · Q3 2026
  1. VOXZOGO24%
  2. VIMIZIM21%
  3. GALAFOLD15%
  4. PALYNZIQ11%
  5. NAGLAZYME11%
  6. ALDURAZYME6%
  7. BRINEURA5%
  8. POMBILITI + OPFOLDA5%
  9. KUVAN2%
  10. ROCTAVIAN<1%

Latest Activity

BMRNBioMarin
Q3 2026
EPS
$0.23
est -$0.11+$0.34
Revenue
$1.02B
est $1.02B+0.2%

BioMarin slashed full-year non-GAAP EPS guidance to $2.80-$3.10 from $4.90-$5.10 on Alesta and BMN 450 charges. Revenue crossed $1 billion for the first time on the Amicus deal, but a large international VOXZOGO order slipped into Q4.

Quarterly EPS — reported vs estimate

BMRN Coverage

Frequently Asked Questions

What does BioMarin do?

BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company that develops and commercializes medicines for people with genetically defined conditions. It has nine commercial therapies plus a clinical and preclinical pipeline.

What is the BMRN stock price target?

24/7 Wall St.'s 12-month price target for BMRN is $89.46, rated Buy. The Wall Street consensus target is $90.19. BMRN price prediction →